493 results on '"Ghofrani, H. A."'
Search Results
2. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era
3. Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary Hypertension
4. Estimation of probabilistic seismic sliding displacement and pseudo-static coefficients (k15) for seismic stability assessment of slopes in the southern Lower Mainland, British Columbia
5. Consistency of the Efficacy and Safety Profile of Sotatercept across Baseline Cardiac Index Subgroups: A Pooled Analysis of STELLAR and PULSAR Trials
6. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
7. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
8. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
9. Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
10. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
11. Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study
12. Patient-Reported Long-Term Outcome of Balloon Pulmonary Angioplasty for Inoperable CTEPH
13. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: A COMPERA analysis
14. Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study
15. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
16. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
17. Body fluid status in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
18. Right atrial pressure to pulmonary artery wedge pressure ratio in chronic thromboembolic pulmonary hypertension
19. Impact of pulmonary arterial hypertension on employment, work productivity and quality of life - results of a cross-sectional multi-center study
20. Childhood Trauma in patients with PAH -prevalence, impact on QoL and mental health - a preliminary report
21. Effect of sotatercept on multicomponent improvement in the PULSAR study
22. Pulmonale Hypertonie
23. Therapie des akuten und chronischen Rechtsherzversagens
24. Pulmonale Hypertonie
25. Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome
26. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis
27. Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension
28. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry
29. Erkrankungen der Atmungsorgane
30. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
31. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis
32. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
33. Klinische Relevanz der rechts-atrialen Funktion bei Patienten mit pulmonal-arterieller Hypertonie
34. CEACAM6 Impedes the HO-1-Mediated Defence Against Nitrosative/Oxidative Stress in COPD
35. (161) - Consistency of the Efficacy and Safety Profile of Sotatercept across Baseline Cardiac Index Subgroups: A Pooled Analysis of STELLAR and PULSAR Trials
36. The effect of bismuth subcitrate in patients with diarrhea predominant irritable bowel syndrome
37. ERS statement on chronic thromboembolic pulmonary hypertension
38. Does Age Matter? Pulmonary Endarterectomy in the Elderly Patient with CTEPH
39. Abstract 10188: Sotatercept Phase 3 Program Design and Rationale: A Novel Treatment for Pulmonary Arterial Hypertension
40. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
41. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
42. Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy
43. Supplement to: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
44. Supplement to: Riociguat for the treatment of pulmonary arterial hypertension.
45. Pulmonary Hypertension in Patients With COPD
46. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
47. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
48. Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry
49. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
50. COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.